<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30078507</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>23</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1095-6859</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>151</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Gynecologic oncology</Title>                <ISOAbbreviation>Gynecol. Oncol.</ISOAbbreviation>            </Journal>            <ArticleTitle>BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.</ArticleTitle>            <Pagination>                <MedlinePgn>145-152</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0090-8258(18)31088-6</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ygyno.2018.07.024</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the BRCA status in Chinese patients with ovarian cancer (OC). Though there were two large prevalence studies in Chinese OC patients, this was the first time to observe it in healthy controls.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We performed BRCA mutation screening using next-generation sequencing to determine the prevalence of BRCA germline deleterious mutations in an unselected cohort of Chinese OC patients (n = 1331) versus healthy controls (n = 1763) and describe the types and spectrum of BRCA deleterious variants.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 1331 patients with OC, 227 (17.1%) carried deleterious variants in BRCA1 and 70 (5.3%) carried deleterious variants in BRCA2. Of 1763 control subjects, 6 (0.3%) and 2 (0.1%) had deleterious variants in BRCA1 and BRCA2. No patient carried mutations in both BRCA1 and BRCA2 simultaneously. Sixty-three novel mutations were identified, and three Chinese specific hot-spot mutations were notified as BRCA1 c.5470_5477delATTGGGCA, BRCA1 c.981_982delAT, and BRCA1 c.3770_3771delAG. Interestingly, all these high-frequency recurrent mutations were distributed on exon 10, which may also be the Chinese OC BRCA mutations' distinct characteristics. In addition, in our study, the estimated odds ratio (OR) of OC associated with BRCA1 positive variants were approximately 34.6 (95% CI, 12.5-95.7) in age group under 40 and 42.4 (95% CI, 5.9-305.2) in group older than 50 in the Chinese population, respectively.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We recommend BRCA testing to all Chinese OC patients and those general Chinese who have family members with hereditary breast and ovarian related cancer (HBOC)-related cancers. Variants carriers would not only benefit from early prevention of OC but also for the medical management.</AbstractText>                <CopyrightInformation>Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Ang</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>TopGene Tech Co., Ltd., Guangzhou, 510025, Guangdong, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xie</LastName>                    <ForeName>Rong</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, The Teaching Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, 350014, Fujian, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhi</LastName>                    <ForeName>Qihuan</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>TopGene Tech Co., Ltd., Guangzhou, 510025, Guangdong, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Deng</LastName>                    <ForeName>Yixiao</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>TopGene Tech Co., Ltd., Guangzhou, 510025, Guangdong, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wu</LastName>                    <ForeName>Yangming</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>TopGene Tech Co., Ltd., Guangzhou, 510025, Guangdong, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Weiwei</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>TopGene Tech Co., Ltd., Guangzhou, 510025, Guangdong, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Lu</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>TopGene Tech Co., Ltd., Guangzhou, 510025, Guangdong, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jiao</LastName>                    <ForeName>Zinan</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>TopGene Tech Co., Ltd., Guangzhou, 510025, Guangdong, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Luo</LastName>                    <ForeName>Jiaqi</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>TopGene Tech Co., Ltd., Guangzhou, 510025, Guangdong, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zi</LastName>                    <ForeName>Yi</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>TopGene Tech Co., Ltd., Guangzhou, 510025, Guangdong, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sun</LastName>                    <ForeName>Gang</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>TopGene Tech Co., Ltd., Guangzhou, 510025, Guangdong, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Jiajia</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>TopGene Tech Co., Ltd., Guangzhou, 510025, Guangdong, PR China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shi</LastName>                    <ForeName>Yujian</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>TopGene Tech Co., Ltd., Guangzhou, 510025, Guangdong, PR China. Electronic address: yujian.shi@topgene.cn.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Jian</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, The Teaching Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, 350014, Fujian, PR China. Electronic address: liujianfj@126.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>02</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Gynecol Oncol</MedlineTA>            <NlmUniqueID>0365304</NlmUniqueID>            <ISSNLinking>0090-8258</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">BRCA gene</Keyword>            <Keyword MajorTopicYN="N">Case-control studies</Keyword>            <Keyword MajorTopicYN="N">Chinese genetic testing</Keyword>            <Keyword MajorTopicYN="N">Exon mutation</Keyword>            <Keyword MajorTopicYN="N">High-throughput nucleotide sequencing</Keyword>            <Keyword MajorTopicYN="N">Ovarian neoplasms</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>31</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30078507</ArticleId>            <ArticleId IdType="pii">S0090-8258(18)31088-6</ArticleId>            <ArticleId IdType="doi">10.1016/j.ygyno.2018.07.024</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>